Clinical analysis of 15 patients with Waldenstr?m macroglobulinemia received bortezomib-based treatment

ABSTRACT

Objective To summarize the clinical experience of bortezomib-based treatment for Waldenstr?m macroglobu-linemia and evaluate the therapeutic efficacy and safety .Methods The clinical data were collected for 15 patients with Waldenstr?m macroglobulinemia receiving bortezomib-based treatment from December 2008 to October 2015 .Three therapeutic regimens included BD (bortezomib and dexamethasone) in one case ,RBD (bortezomib ,rituximab and dexamethasone) in three cases and BCD (bortezomib ,dexamethasone and cyclophosphamide) in eleven cases .Responses ,adverse reactions and survival analysis were evaluated respectively .Results The overall response rate and major response rate were 93 .3% and 80% inclu-ding CR 1 case ,VGPR 2 cases ,PR 9 cases and MR 2 cases .The common adverse events included gastrointestinal (53 .3% ) , leukopenia (20% ) ,infection (20% ) and peripheral neuropathy (26 .7% ) .After a median follow-up of 21 (3-85) months ,the median PFS (progression-free survival) time was 21 (3-36) months and 1 year PFS rate was 83 .3% .Survival analysis showed that two prognostic risk factors related to PFS were high-risk group based on international prognostic scoring system for WM (IPSSWM )(P=0 .015) and the low response to treatment (< PR) (P=0 .024) .Conclusion Bortezomib-based therapeutic regimensexhibited significant efficacyfor patients with WM .IPSSWM and the responses to treatment can be usedto monitor the disease progression and evaluate the therapeutic result .